Innovation and Commercialization of Therapeutics for Metabolic Disorders

Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Reply New Message

Prev Message Back To Forum Threaded View Next Message

brentie98

Rank: President [?]

Points: 5496 [?]

Votes: 21 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Innovation and Commercialization of Therapeutics for Metabolic Disorders

posted on Feb 03, 2013 12:37PM

Date: 2/11/2013 - 2/12/2013

City: Baltimore

Country: United States

Keynote: Natalia Borinshteyn, Head of Portfolio Strategy, Novel Prevention & Cure Approaches, Global Diabetes, SANOFI, Anders Boss, CSO, MANNKIND CORPORATION, William Daley, Vice President, Cardiovascular Thrombosis, SANOFI, Stephen Davis, Professor of Physiology, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, Alexander Fleming, CMO, EXSULIN, Claudia Graham, Vice President, Marketing, DEXCOM, Mark Heiman, CSO, NUMEHEALTH, Alissa Heizler-Mendoza, Senior Medical Science Liaison, AMYLIN PHARMACEUTICALS, Brian Hubbard, Director, Therapeutics Discovery & Development, BROAD INSTITUTE, Dennis Kim, CMO, ZAFGEN

Agenda topics:

Regulatory Update Understand FDA Expectations for New Drugs for Diabetes and Obesity
Design Your Diabetes & Obesity Drug Development Program to Fulfill the Needs for Safety Testing Requirements
Devise a Clear Path Forward for International Regulatory Approval of your Metabolic Drug
Breakthroughs in Insulin Pharmacodynamics: The State of the Art and the Shape of the Future
The Next Unmet Need: Drugs for Core and Co-Morbid Diabetic Conditions
Metabolic Effects of MetAP2 Inhibition: A Novel Pathway to Energy Homeostasis
Adressing Future Unmet Medical Need in Diabetic Patients: Implications for Selection of Drug Targets and Design of Clinical Studies
Achieve Clearer, More Significant Clinical Trial Metabolic Endpoints
Avoiding Late-Stage and Post-Launch Toxicity
The Next Steps in Novel Treatments for Type-1 Diabetes
Challenges in Anti-Diabetic Drug Development: A Shift from Surrogate to Outcome Trials
Utility of Preclinical Metabolic Models

Innovation and Commercialization of Therapeutics for Metabolic Disorders
For more information please visit the website.
>> Visit conference website

http://www.antibodies-online.com/conference/842/Innovation-and-Commercialization-of-Therapeutics-for-Metabolic-Disorders/

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply